ArticleWorld journal of plastic surgery2018
Efficacy of Topical Enalapril in Treatment of Hypertrophic Scars.
Article in World journal of plastic surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Interventions for postburn pruritus.The Cochrane database of systematic reviews · 2024Pooled it
- Evidence-based therapy in hypertrophic scars: An update of a systematic review.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society · 2020Pooled it
- Efficacy of Topical Losartan in Management of Mammoplasty and Abdominoplasty Scars: A Randomized, Double-Blind Clinical Trial.Aesthetic plastic surgery · 2022Trial
- An Integrated Text Mining Approach for Discovering Pharmacological Effects, Drug Combinations, and Repurposing Opportunities of ACE Inhibitors.International journal of molecular sciences · 2026Article
- Beyond blood pressure: the renin-angiotensin system as an innovative driver and therapeutic target in pathological scarring.Frontiers in pharmacology · 2026Review
- Endothelial system dysregulation underlies keloid development and therapeutic targeting.Frontiers in cell and developmental biology · 2026Review
- Pharmacotherapy for Keloids and Hypertrophic Scars.International journal of molecular sciences · 2024Review
- Article
- Targeting the Angiotensin Pathway in the Treatment of Cutaneous Fibrosis: A Systematic Review.JID innovations : skin science from molecules to population health · 2023Review
- Evidence-based management of keloids and hypertrophic scars in dermatology.Archives of dermatological research · 2023Review
- Progress in the clinical treatment of keloids.Frontiers in medicine · 2023Review
- Keloids: a review of therapeutic management.International journal of dermatology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAngiotensin II activation by angiotensin-converting enzyme (ACE) is a significant mediator in wound healing and collagen production. In this study, the effect of topical application of ACE on hypertrophic scar formation has been studied in a clinical trial.
methodsThirty patients with hypertrophic scar and itching after treatment of 2
resultsThe mean size of scars in enalapril treated side was significantly less than scars in the placebo side. Additionally, enalapril treated scars had significantly lower itching scores compared to the placebo group.
conclusionTopical enalapril significantly decreases the clinical parameters of hypertrophic scar and also itching as an indirect indicative of scar improvement. Furthermore, enalapril proved to be clinically safe for patients with low incidence of adverse drug reactions and acceptable cost effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.